8-K: Madrigal Pharmaceuticals Appoints Jacqualyn Fouse to Board, Fred Craves to Retire

Madrigal Pharmaceuticals announced the appointment of Jacqualyn Fouse to its Board of Directors and the upcoming retirement of Fred Craves in July 2025.

Summary

• Madrigal Pharmaceuticals has appointed Jacqualyn (Jackie) Fouse, Ph.D., to its Board of Directors.
• Fred Craves, Ph.D., will retire from the Board in July 2025.
• Dr. Fouse will serve as a Class III director and will stand for re-election at the annual meeting.
• She is expected to join the Boards Audit Committee and Nominating and Governance Committee.
• As a non-employee director, Dr. Fouse will receive an annual cash fee of $50,000.
• She will also be entitled to $12,500 and $6,000 annually for her service on the Audit Committee and Nominating and Governance Committee, respectively.
• Dr. Fouse received an equity grant with a value of $600,000, consisting of 50% stock options and 50% restricted stock units.
• The stock options will vest as to 50% on March 10, 2026, and 12.5% every three months thereafter.
• Half of the restricted stock units will vest on March 10, 2026, and the remaining half on March 10, 2027.
• Dr. Fouse will also be entitled to an annual award consistent with other non-employee directors.
• Madrigal's medication, Rezdiffra (resmetirom), is approved by the FDA for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3).
• An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).

Sentiment

Score: 7

Explanation: The sentiment is positive due to the appointment of an experienced executive to the board and the company's focus on expanding its presence in the MASH market. However, risks associated with commercialization and clinical trials temper the overall sentiment.

Positives

• The appointment of Jacqualyn Fouse, an experienced biotech executive, is expected to be a tremendous asset for Madrigal.
• Dr. Fouse's experience includes executive leadership roles at Agios Pharmaceuticals and Celgene Corporation.
• Madrigal has successfully developed and launched Rezdiffra, the first approved treatment for MASH, demonstrating a compelling benefit for patients.
• Madrigal is committed to long-term leadership in MASH and is expanding geographically and advancing its clinical program.

Risks

• The forward-looking statements are subject to risks and uncertainties, including regulatory approvals, commercial launch challenges, and clinical trial outcomes.
• Madrigal has a history of operating losses and may not achieve or maintain profitability.
• There are risks associated with meeting the objectives of Madrigal's clinical trials, including enrollment and safety events.
• Market demand for and acceptance of Rezdiffra is uncertain.
• The potential inability to raise sufficient capital to fund ongoing operations is a risk.

Future Outlook

Madrigal plans to drive the launch of Rezdiffra, expand geographically, advance its clinical program in compensated MASH cirrhosis, and build its pipeline.

Management Comments

• Julian Baker, Chairman of the Board, stated that Jackie Fouse will be a tremendous asset for Madrigal as the Company continues to grow and evolve.
• Bill Sibold, Chief Executive Officer of Madrigal, stated that Jackie Fouse's appointment reflects Madrigal's commitment to long-term leadership in MASH.
• Dr. Fouse stated she is thrilled to be joining the Board of Directors of Madrigal, a company that has transformed care for patients with MASH.

Industry Context

Madrigal's announcement comes as the company is focused on commercializing Rezdiffra, the first approved treatment for MASH, a liver disease with high unmet medical need. The appointment of an experienced executive like Dr. Fouse signals Madrigal's commitment to expanding its presence in the MASH market.

Comparison to Industry Standards

• Dr. Fouse's previous role as CEO of Agios Pharmaceuticals and executive roles at Celgene Corporation provide her with experience comparable to leaders at other major biopharmaceutical companies such as Gilead Sciences and Vertex Pharmaceuticals.
• The equity grant awarded to Dr. Fouse is consistent with compensation packages offered to non-employee directors at publicly traded biotech companies.
• Madrigal's focus on MASH and the development of Rezdiffra positions it as a leader in a competitive landscape that includes companies like Intercept Pharmaceuticals and Genfit, which are also developing treatments for liver diseases.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may view the appointment of Dr. Fouse positively, given her experience and expertise.
• Employees may be encouraged by the company's commitment to long-term leadership in MASH.
• Patients with MASH may benefit from Madrigal's continued focus on developing and commercializing novel therapeutics.

Next Steps

• Dr. Fouse will join the Board's Audit Committee and Nominating and Governance Committee.
• Dr. Fouse will stand for re-election at the annual meeting of stockholders.
• Madrigal will continue to focus on the launch of Rezdiffra and expansion of its clinical program.

Key Dates